Literature DB >> 28983771

Endoscopic and Imaging Predictors of Complete Pathologic Response After Chemoradiation for Esophageal Cancer.

Guneesh S Uberoi1, Angad S Uberoi1, Manoop S Bhutani2.   

Abstract

PURPOSE OF REVIEW: Locally advanced esophageal cancer is frequently treated preoperatively with chemotherapy and radiation. The degree of response to this preoperative therapy varies in different patients, and a complete pathological response (pCR) has important implications in the management and prognosis of these patients. This is a review of the different modalities currently available to detect pCR and the clinical context of their use. RECENT
FINDINGS: While research is still ongoing, no single technique has emerged as the modality of choice to reliably predict pCR in all patients. Studies investigating the sensitivity, specificity, and accuracy of these modalities have had promising results, but no single modality has been firmly validated as the modality if choice. The emergence of functional imaging techniques and the use of biomarkers are newer developments which need further evaluation before adoption in routine clinical practice. While no single technique reliably predicts pCR, a combination of imaging and diagnostic modalities (endoscopic appearance, biopsy, EUS, and PET/CT) may provide a better diagnostic yield rather than any of these modalities taken alone.

Entities:  

Keywords:  Endoscopic ultrasound (EUS); Neoadjuvant chemoradiation therapy (nCRT); Pathologic complete response (pCR); Positron emission tomography/computed tomography (PET/CT)

Mesh:

Substances:

Year:  2017        PMID: 28983771     DOI: 10.1007/s11894-017-0594-5

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  31 in total

1.  Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  Peter S N van Rossum; Astrid L H M W van Lier; Marco van Vulpen; Onne Reerink; Jan J W Lagendijk; Steven H Lin; Richard van Hillegersberg; Jelle P Ruurda; Gert J Meijer; Irene M Lips
Journal:  Radiother Oncol       Date:  2015-05-19       Impact factor: 6.280

2.  Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02).

Authors:  Christian Jost; Janek Binek; Jan C Schuller; Peter Bauerfeind; Urs Metzger; Baseli Werth; Juerg Knuchel; Jean-Louis Frossard; Philipp Bertschinger; Peter Brauchli; Christa Meyenberger; Thomas Ruhstaller
Journal:  Gastrointest Endosc       Date:  2010-03-20       Impact factor: 9.427

3.  Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma.

Authors:  Joseph Willis; Gregory S Cooper; Gerard Isenberg; Michael V Sivak; Nathan Levitan; Julie Clayman; Amitabh Chak
Journal:  Gastrointest Endosc       Date:  2002-05       Impact factor: 9.427

4.  Global incidence of oesophageal cancer by histological subtype in 2012.

Authors:  Melina Arnold; Isabelle Soerjomataram; Jacques Ferlay; David Forman
Journal:  Gut       Date:  2014-10-15       Impact factor: 23.059

5.  ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.

Authors:  J A Ajani; X Wang; S Song; A Suzuki; T Taketa; K Sudo; R Wadhwa; W L Hofstetter; R Komaki; D M Maru; J H Lee; M S Bhutani; B Weston; V Baladandayuthapani; Y Yao; S Honjo; A W Scott; H D Skinner; R L Johnson; D Berry
Journal:  Mol Oncol       Date:  2013-10-28       Impact factor: 6.603

6.  Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.

Authors:  Paul M Schneider; Ralf Metzger; Hartmut Schaefer; Frank Baumgarten; Daniel Vallbohmer; Jan Brabender; Eva Wolfgarten; Elfriede Bollschweiler; Stephan E Baldus; Hans P Dienes; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

7.  The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.

Authors:  Peter S N van Rossum; David V Fried; Lifei Zhang; Wayne L Hofstetter; Marco van Vulpen; Gert J Meijer; Laurence E Court; Steven H Lin
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

Review 8.  Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.

Authors:  Peter S N van Rossum; Lucas Goense; Jihane Meziani; Johannes B Reitsma; Peter D Siersema; Frank P Vleggaar; Marco van Vulpen; Gert J Meijer; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Gastrointest Endosc       Date:  2015-11-26       Impact factor: 9.427

9.  Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus.

Authors:  Tomonori Nakanoko; Hiroshi Saeki; Masaru Morita; Yuichiro Nakashima; Koji Ando; Eiji Oki; Takefumi Ohga; Yoshihiro Kakeji; Yasushi Toh; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2013-09-25       Impact factor: 5.344

10.  Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Yu-suo Tong; Xi-lei Zhou; Xiao-wei Wang; Qing-quan Wu; Tong-xin Yang; Jin Lv; Jin-song Yang; Bin Zhu; Xiu-feng Cao
Journal:  J Transl Med       Date:  2014-08-29       Impact factor: 5.531

View more
  1 in total

1.  Can Clinical Response Predict Pathologic Response Following Neoadjuvant Chemoradiation for Esophageal Cancer?

Authors:  Puja G Khaitan; Tyler Holliday; Austin Carroll; Wayne L Hofstetter; Erin M Bayley; Nicolas Zhou; Sameer Desale; Thomas J Watson
Journal:  J Gastrointest Surg       Date:  2022-04-12       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.